ArticleFrontiers in oncology2021

Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study.

Ya Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.